ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 91

Histonedeacetylase 1 (HDAC1): A Key Mediator of T Cells for the Pathogenesis of Rheumatoid Arthritis

Lisa Goschl 1, Victoria Saferding 1, Nicole Boucheron 2, Johan Backlund 3, Alexander Platzer 1, Kiyoshi Hirahara 4, Han-yu Shih 5, Patrick Matthias 6, Clemens Scheinecker 1, Günter Steiner 7, Wilfried Ellmeier 2 and Michael Bonelli1, 1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 2Institute of Immunology, Division of Immunobiology, Medical University of Vienna, Vienna, Austria, 3Medical Inflammation Research, Karolinska Institute; Department of Medical Biochemistry and Biophysics, Stockholm, Sweden, 4Graduate School of Medicine, Chiba University, Chiba, Japan, 5National Institute of Arthritis, National Institutes of Health, Bethesda, 6Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland, 7Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Vienna, Austria, Vienna, Austria

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: adaptive immunity, epigenetics and CD T cells, grip strength, Type II collagen

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Despite enormous efforts to develop new therapeutic strategies for treatment of rheumatoid arthritis (RA), the large number of non responding patients to currently available drugs underlies the unmet need to identify new therapeutic targets.  Certain CD4+T cell subsets, especially Th17 cells, have been shown to be major drivers of inflammation in patients with RA. The expression of their key transcription factors is controlled by histone modifications which includes acetylation of lysine residues mediated by histone deacetylases (HDAC). Indeed, pan HDAC inhibitors have been shown to be a potential therapeutic strategy. However, major side effects limited the clinical use and underline the need of more specific HDAC inhibitors. We therefore addressed the individual role of HDAC1 on the development of collagen-induced arthritis model (CIA).

Methods: Methods: Mice with a T cell specific deletion of HDAC1 (HDAC1cKO) were generated by using the CD4Cre/LoxP system. Collagen induced arthritis (CIA) was induced at week 8. Animals were scored for paw swelling and grip strength. After 10 weeks, mice were sacrificed and paraffin sections of the affected joints were analysed for histomorphologic signs of inflammation, cartilage and bone destruction. Anti-CII antibody levels were determined by ELISA. Serum samples were analysed for various cytokines by multiplex assays. CCR6 expression in CD4 T cells was analysed by flow cytometry.

Results: To address potential effects of HDAC1 in the pathogenesis of RA, CIA was induced in HDAC1cKO mice and WT mice. Surprisingly HDAC1cKO mice were completely protected from the development of arthritis. In line with the clinical data, histological analysis revealed no signs of inflammation, no bone erosion and no osteoclasts in the joints of HDAC1cKO mice. Anti-CII antibodies, including total IgG and igG2c were detected in HDAC1cKO and WT mice. Surprisingly, IL-17 was significantly decreased in the serum of HDAC1cKO mice as compared to WT mice, suggesting a role of HDAC1 in the development of Th17 cells. To see whether HDAC1 is involved in the regulation of the chemokine receptor 6 (CCR6), the main marker of Th17 cells, we compared the upregulation of CCR6 in CD4+ T cells from WT and HDAC1cKO mice. Indeed, CCR6 could not be upregulated in CD4+ T cells from HDAC1cKO mice upon IL-6 in vitro. These data support the role of HDAC1 in the regulation of CCR6, an important chemokine receptor, which is necessary for the migration of pathogenic Th17 cells and therefore for the development of arthritis.

Conclusion: Our data show the importance of HDAC1 as a key immune regulator in the pathogenesis of T cell driven collagen induced arthritis. Therefore, it might be considered as an interesting novel therapeutic target in RA. 


Disclosure: L. Goschl, None; V. Saferding, None; N. Boucheron, None; J. Backlund, None; A. Platzer, None; K. Hirahara, None; H. Shih, None; P. Matthias, None; C. Scheinecker, None; G. Steiner, None; W. Ellmeier, None; M. Bonelli, None.

To cite this abstract in AMA style:

Goschl L, Saferding V, Boucheron N, Backlund J, Platzer A, Hirahara K, Shih H, Matthias P, Scheinecker C, Steiner G, Ellmeier W, Bonelli M. Histonedeacetylase 1 (HDAC1): A Key Mediator of T Cells for the Pathogenesis of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/histonedeacetylase-1-hdac1-a-key-mediator-of-t-cells-for-the-pathogenesis-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/histonedeacetylase-1-hdac1-a-key-mediator-of-t-cells-for-the-pathogenesis-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology